Induced pluripotency and gene editing in fanconi anemia

Susana Navarro, Alessandra Giorgetti, Angel Raya, Jakub Tolar

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Induced pluripotent stem cells (iPSCs) represent an invaluable tool in a chromosomal instability syndrome such as Fanconi anemia (FA), as they can allow to study of the molecular defects underlying this disease. Many other applications, such as its use as a platform to test different methods or compounds, could also be of interest. But the greatest impact of iPSCs may be in bone marrow failure diseases, as iPSCs could represent an unlimited source of autologous cells to apply in advanced treatments such as gene therapy. At the same time, genome editing constitutes the next generation of technology to further develop a safer, personalized, targeted gene therapy. Despite the promising advantages that these two technologies would present in a disease such as FA, the specific characteristics of the disease make both of these processes especially challenging. Efficient and safer FA-hiPSC (human induced pluripotent stem cell) generation methods, robust and reliable differentiation protocols for iPSCs, as well as really efficient delivery methods to perform targeted gene correction should be developed.

Original languageEnglish (US)
Pages (from-to)321-328
Number of pages8
JournalCurrent gene therapy
Volume16
Issue number5
DOIs
StatePublished - Oct 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Bentham Science Publishers.

Keywords

  • Fanconi anemia
  • Gene editing
  • Gene therapy
  • Induced pluripotent stem cells

Fingerprint

Dive into the research topics of 'Induced pluripotency and gene editing in fanconi anemia'. Together they form a unique fingerprint.

Cite this